Ibogaine Infusion

Clinical-luxury · Screening-first

IV ibogaine infusion: physician-supervised, monitored, screening-first

Physician-supervised intravenous psychoactive ibogaine in a medical infusion setting — consult, cardiac screening, continuous monitoring, and structured integration afterward.

Definition

IV ibogaine infusion (also called intravenous ibogaine) is the psychoactive delivery of ibogaine by intravenous infusion under physician supervision. The patient journey parallels ketamine infusion clinics: consult → cardiac screening → monitored IV infusion → integration. Continuous ECG/telemetry is non-negotiable because ibogaine can prolong the QTc interval.

Evidence gap: Most published clinical literature — including Cherian et al., Nature Medicine 2024 — describes oral ibogaine HCl, often with IV magnesium support, not IV ibogaine as the psychoactive dose. Controlled evidence for psychoactive IV ibogaine remains sparse. Ibogaine is U.S. Schedule I and not FDA-approved.

On this site, “infusion” is not a spa label for oral dosing with a saline lock. Support IV ≠ psychoactive IV. Read the definition hub.

Cardiac safety (non-negotiable)

  • Pre-treatment ECG and medication/electrolyte review
  • Continuous cardiac monitoring during the high-risk window
  • Physician oversight and emergency preparedness
  • Written clarity on psychoactive route and any concurrent support IV

Safety & screening · ECG checklist

How the medical journey works

  1. Consult — history, goals, medications, contraindications
  2. Cardiac & medical screening — ECG, labs as indicated, go/no-go
  3. Monitored IV infusion — psychoactive intravenous ibogaine + telemetry
  4. Integration / aftercare — psychosocial planning after the acute window

Step-by-step: how it works. Cost diligence: cost overview · clinic vetting.

Compare carefully

Homepage FAQ

What is IV ibogaine infusion?

Intravenous delivery of ibogaine as the psychoactive treatment under physician supervision in a medical infusion setting, with cardiac screening, continuous monitoring, and integration afterward.

Is published research mostly oral?

Yes. Landmark examples include Knuijver et al. (Addiction, 2021; oral HCl, QTc) and Cherian et al. (Nature Medicine, 2024; oral ibogaine + IV magnesium). Controlled IV-psychoactive evidence is sparse.

Is ibogaine FDA-approved?

No. It is not FDA-approved for any indication and is Schedule I in the United States.

Is cardiac screening required?

Yes. Ibogaine can prolong QTc. Screening and continuous monitoring are ethical and clinical non-negotiables for any medical program.

How do I start?

Read safety and how-it-works education, then submit a confidential screening request at /apply.

Start with safety, then request screening

Start with a confidential inquiry. Screening comes before any treatment conversation — not after a sales pitch.

Check if you qualify